 Anavex Life Sciences Corp. NASDAQ: AVXL shares traded higher Monday after the company announced ANAVEX2-73, the companys main pipeline drug, improved both primary cognitive and secondary MDS-UPDRS efficacy endpoints with significant biomarker correlation in placebo-controlled Phase 2 clinical trial for treatment of Parkinsons disease. Anavex Life Sciences was up 18.37 at 29.30 at last check. 